The Food and Drug Administration approved a personalized cellular therapy treatment for leukemia developed by researchers at the University of Pennsylvania and Children’s Hospital of Philadelphia.
The T-Cell therapy, which will be marketed by Novartis as Kymriah, was OK'd as treatment for patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia that is refractory, or in second or later relapse.
In 2012, Penn and Novartis — a Swiss drug company that has its U.S headquarters in New York — entered into a global collaboration to further research, develop and commercialize Kymriah and other CAR-T cell therapies for the treatment of cancers.
Breaking news and the stories that matter to your neighborhood.
The therapy treats cancer by boosting the ability of a patient's own immune systems to identify and kill tumors is based on technology developed by a team of researchers led by Dr. Carl June, director of the Center for Cellular Immunotherapies at Penn's Abramson Cancer Center.
To read the full story, click here.
For more business news, visit Philadelphia Business Journal.